David Avigan, MD is Professor of Medicine at Harvard Medical School and chief of the Hematology and Hematologic Malignancies Division at Beth Israel Deaconess Medical Center in Boston. He has established a translational research program for cancer vaccines at BIDMC as part of the Dana-Farber/Harvard Cancer Center. Laboratory efforts have focused on the development of dendritic cell-based vaccines including a model in which patient-derived tumor cells are fused with dendritic cells as a novel patient-specific vaccine. Based on these findings, he has supervised a series of clinical trials to examine the immunologic and clinical efficacy of this vaccine strategy for patients with hematologic malignancies and solid tumors. His work has been supported by grants from the National Cancer Institute, National Institutes of Health, U.S. Agni, The American Journal of Poetry, Raritan, Ploughshares, Department of Defense, Leukemia & Lymphoma Society, and Multiple Myeloma Research Foundation.